Investigations into the role of anti‐HLA class II antibodies in TRALI
- 6 February 2003
- journal article
- case report
- Published by Wiley in Transfusion
- Vol. 43 (2), 185-191
- https://doi.org/10.1046/j.1537-2995.2003.00285.x
Abstract
BACKGROUND : TRALI is thought to be triggered by recipient‐specific anti‐HLA class I or antibodies against neutrophils in donor plasma. Recently, anti‐HLA class II have also been implicated. The prevalence of anti‐HLA class II was investigated in normal volunteer platelet donors and in two nonfatal TRALI cases utilizing a flow‐based assay. Potential target antigens also were investigated. STUDY DESIGN AND METHODS : Commercial flow cytometry‐based assays (FlowPRA, One Lambda, Inc.) for anti‐HLA class I and II were compared with standard lymphocytotoxicity tests. Subsequently, 151 volunteer platelet donors and two clinical cases of TRALI were screened with FlowPRA. Immunohistochemical studies were performed on lung tissue from a surgical case, an autopsy case, and a fatal TRALI case. RESULTS : The FlowPRA assays showed moderate concordance for anti‐HLA class I (κ = 0.448) and good concordance for class II antibodies (κ = 0.801), when compared to standard lymphocytotoxicity assays. Ten and 9 percent of female platelet donors were positive for anti‐HLA class I and class II, respectively. Two nonfatal cases of TRALI showed both anti‐HLA class I and anti‐HLA class II. Immunohistochemical analysis of a TRALI case revealed granulocyte aggregation in alveolar capillaries with activated vascular endothelial cells. HLA class II antigen expression was not present on vascular endothelium or intravascular WBCs; however, strong expression was seen on alveolar macrophages. CONCLUSION : FlowPRA assays often detect anti‐HLA class I not detected by conventional lymphocytotoxicity assays. These assays reveal anti‐HLA class II in normal female donor plasma and in sera implicated in TRALI. Immunohistochemical studies failed to reveal endothelial or intravascular‐WBC HLA class II antigen expression in lung tissue derived from TRALI cases or controls, but demonstrated HLA class II expression on pulmonary macrophages.Keywords
This publication has 29 references indexed in Scilit:
- A randomized controlled trial oftransfusion‐related acute lung injury: is plasma from multiparous blood donors dangerous?Transfusion, 2001
- Transfusion‐related acute lung injury: femme fatale?Transfusion, 2001
- Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model.JCI Insight, 1998
- The association of biologically active lipids with the development of transfusion‐related acute lung injury: a retrospective studyTransfusion, 1997
- The biology of PECAM-1.JCI Insight, 1997
- Stored Blood Components Contain Agents That Prime the Neutrophil NADPH Oxidase through the Platelet‐Activating‐Factor ReceptorVox Sanguinis, 1992
- Reports of 355 transfusion‐associated deaths: 1976 through 1985Transfusion, 1990
- Transfusion‐related acute lung injury caused by an NB2 granulocyte‐ specific antibody in a patient with thrombotic thrombocytopenic purpuraTransfusion, 1990
- Diagnostic and pathogenetic considerations in transfusion‐related acute lung injuryTransfusion, 1985
- PULMONARY MICROVASCULAR ALTERATIONS AND INJURY INDUCED BY COMPLEMENT FRAGMENTS: SYNERGISTIC EFFECT OF COMPLEMENT ACTIVATION, NEUTROPHIL SEQUESTRATION, AND PROSTAGLANDINSAnnals of the New York Academy of Sciences, 1982